Notice: This company recently went public with an IPO on Friday, September 13th 2024. They issued 17,500,000 shares at $18.00 per share. We will continue to update data for BCAX as it becomes available.

Bicara Therapeutics (BCAX) Insider Trading & Ownership

$25.25

-0.48 (-1.87%)

(As of 11:29 AM ET)

Compare

Number Of Insiders Buying (Last 12 Months): 2
Amount Of Insider Buying (Last 12 Months): $34.25 M
Number Of Insiders Selling (Last 12 Months): 0

Get BCAX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Bicara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

BCAX Insider Buying and Selling by Quarter

Ad DTI

Massive shakeup in defense contracting

There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.

You need to check out the full story right here.

Bicara Therapeutics Insider and Congressional Trades History

Transaction Type

Time Frame

Start Date

End Date

Export to Excel

Transaction Date	Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
9/17/2024	James E Flynn	Major Shareholder	Buy	70,000	$18.00	$1,260,000.00
9/16/2024	Ra Capital Management, L.P.	Director	Buy	1,833,000	$18.00	$32,994,000.00

(Data available from 1/1/2013 forward)

BCAX Insider Trading Activity - Frequently Asked Questions

: The list of insiders at Bicara Therapeutics includes James E Flynn, and Ra Capital Management, L.P.. Learn more on insiders at BCAX.
: The following insiders have purchased BCAX shares in the last 24 months: James E Flynn ($1,260,000.00), and Ra Capital Management, L.P. ($32,994,000.00).
: Insiders have purchased a total of 1,903,000 BCAX shares in the last 24 months for a total of $34,254,000.00 bought.

Bicara Therapeutics Key Executives

Ms. Claire Mazumdar Clemon M.B.A. (Age 35)
Ph.D., CEO & Director
Compensation: $650k
Mr. Ryan Cohlhepp Pharm.D. (Age 48)
President & COO
Compensation: $660k
Mr. Ivan Hyep M.B.A. (Age 40)
Chief Financial Officer
Compensation: $597.5k
Ms. Lara S. Meisner J.D. (Age 52)
Chief Legal Officer & Corporate Secretary
Ms. Rachel Salazar
SVP of R&D Strategy and Operations
Ms. Sathish Hasige
Senior VP and Head of Technical Operations & Supply Chain
Dr. David Raben M.D. (Age 61)
Chief Medical Officer
Ms. Angela Windt
VP & Head of Regulatory Affairs
Dr. Jeltje Schulten M.B.A.
M.D., Senior Vice President of Clinical & Medical Affairs
Mr. Jean-Paul Rodrique
Senior Vice President of Quality